Japan cancels a third of contracted Astrazeneca vaccine purchase | Inquirer News

Japan cancels a third of contracted Astrazeneca vaccine purchase

/ 06:04 PM April 11, 2022

New data finds AstraZeneca booster generates higher antibodies vs Omicron

FILE PHOTO: A test tube labeled with the Vaccine is seen in front of the AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/Illustration

TOKYO — Japan has canceled the purchase of about 40 million AstraZeneca Plc COVID-19 vaccine doses it agreed to buy last year, a health ministry official said in parliament on Monday.

The contract allowed the government to cancel a portion of the supply if it was unneeded, the official said in response to lawmakers’ questioning. Japan had originally agreed to buy 120 million of the shots, with the bulk made domestically by Daiichi Sankyo Co. and other local partners.

Article continues after this advertisement

About 200,000 AstraZeneca doses have been supplied to local governments in Japan, while 63 million doses have donated overseas, the official added.

FEATURED STORIES

Japan has predominantly relied on the mRNA-type vaccines developed by Pfizer Inc and Moderna Inc for its COVID inoculations and boosters so far.

RELATED STORY:
Japan donates AstraZeneca vaccines to PH

Article continues after this advertisement

Japan to lift COVID-19 entry ban for 106 countries including US

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca, Japan

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.